Document is current
Any future updates will be listed below
-
Authors
Ward, Heather
Ajilore, Olusola
Cho, Youngsun
Cooper, Jessica
Dunlop, Boadie
Miller, Andrew
Philip, Noah
Pruett, Brandon
Taylor, Stephan
Tyrka, Audrey
Vogel, Alecia
Goldsmith, David
-
Funding
Funding for this research was provided by:
National Institutes of Health (K23DA059690)
National Institutes of Health (U01MH136062)
National Institutes of Health (R25MH071584)
National Institutes of Health (K01 MH126308)
National Institutes of Health (R25 MH101079)
National Institutes of Health (R25MH101076)
National Institutes of Health (K23 MH127303)
Society of Biological Psychiatry (Special Projects Funding)
- License Information
-
More Information
Article History
Received: 15 August 2025
Accepted: 24 January 2026
First Online: 4 March 2026
Declarations
:
: Dr. Ajilore is the co-founder of KeyWise AI. He serves as a consultant for Otsuka and has served as a consultant for Sage Therapeutics; he is on the advisory board of Embodied Labs and Blueprint. Dr. Cho has received grant funding, travel reimbursements, and speaker fees from Boehringer Ingelheim. Dr. Dunlop has received research support from Beckley PsyTech, Boehringer Ingelheim, Compass Pathways, Intra-Cellular Therapies, NIMH, Reunion Neuroscience, and the Usona Institute, and has served as a consultant for Myriad Neuroscience, and Otsuka. Dr. Miller is a paid consultant for Freedom Biosciences, Cerevel Therapeutics, and Sirtsei Pharmaceuticals, Inc. Dr. Philip has consulted for Motif Neurotech and served on the scientific advisory boards for Pulvinar Neuro and Grey Matter Neurosciences.
